A phase II study to evaluate the safety and efficacy of the combination of ZD1839 (IRESSA), docetaxel and cisplatin in subjects with recurrent and/or metastatic head and neck cancer

Trial Profile

A phase II study to evaluate the safety and efficacy of the combination of ZD1839 (IRESSA), docetaxel and cisplatin in subjects with recurrent and/or metastatic head and neck cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Dec 2007

At a glance

  • Drugs Cisplatin; Docetaxel; Gefitinib
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 16 Dec 2007 Status changed from in progress to completed.
    • 16 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top